About SynCardia
SynCardia is a company based in Tucson (United States) founded in 2001 was acquired by Picardmedia.de in September 2021. SynCardia has raised $60.96 million across 11 funding rounds from investors including Delta Electronics, SWK Holdings and Athyrium Capital Management. SynCardia offers products and services including SynCardia Total Artificial Heart and Emperor Total Artificial Heart. SynCardia operates in a competitive market with competitors including CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave, among others.
- Headquarter Tucson, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Syncardia Systems, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$60.96 M (USD)
in 11 rounds
-
Latest Funding Round
Not available
-
Investors
Delta Electronics
& 5 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SynCardia
SynCardia offers a comprehensive portfolio of products and services, including SynCardia Total Artificial Heart and Emperor Total Artificial Heart.
Temporary replacement for failing hearts in transplant-eligible patients.
Next-generation implantable heart for end-stage cardiac failure support.
Funding Insights of SynCardia
SynCardia has successfully raised a total of $60.96M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SynCardia
SynCardia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Delta Electronics, SWK Holdings and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Tech focused early stage VC firm investing in the US
|
Locked | Locked | Locked | |
|
Versa Capital is focused on private equity investments for business transformation.
|
Locked | Locked | Locked |
Investor details for SynCardia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SynCardia
Investment portfolio details for SynCardia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SynCardia
Detailed financials for SynCardia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syncardia Comparisons
Peer comparison for SynCardia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SynCardia
SynCardia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable technology for hypertension and heart failure is developed.
|
|
| Locked | Locked | Locked |
Implantable battery-powered pumps for ascites removal are developed.
|
|
| Locked | Locked | Locked |
Medical devices for heart failure management are developed.
|
|
| Locked | Locked | Locked |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| Locked | Locked | Locked |
Implantable inter-atrial shunts are developed to treat chronic heart failure.
|
|
| Locked | Locked | Locked |
Minimally invasive ventriculoplasty system for heart failure and FMR
|
Detailed competitors of SynCardia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syncardia
Complete news archive for SynCardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SynCardia
SynCardia was founded in 2001 and raised its 1st funding round 2 years after it was founded.
SynCardia is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
SynCardia is a funded company, having raised a total of $60.96M across 11 funding rounds to date.
SynCardia Systems has developed a temporary total artificial heart in two sizes - 70cc and 50cc. The 70cc product is FDA approved both as a destination therapy and a bridge to transplant. SynCardia also provides a portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home. It claims to have over 1,400 implants accounting for more than 400 patient years. The company filed for an IPO in Aug 2015 and withdrew its application two months later.
SynCardia's top competitors include Sequana Medical, CVRx and Adona Medical.
SynCardia offers SynCardia Total Artificial Heart and Emperor Total Artificial Heart.
SynCardia has 6 investors. Key investors include Delta Electronics, SWK Holdings, Athyrium Capital Management, Highway 12 Ventures, and Picardmedia.de.